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Abstract
Background: Medicine usage in Parkinson's disease patients is often imperfect, in particular
irregular timing of medication. The effect of informing Parkinson's disease patients about the
continuous dopaminergic hypothesis (to encourage regular medicine intake) on medication
adherence and motor control was tested.
Methods: Patients were randomised either to the active group (receiving the intervention) or
control group (no extra information). Antiparkinson medicine usage was monitored for 3 months
before and after the intervention using electronic pill bottles which record the date and time of
opening (MEMS®, Aardex, Switzerland) and data used to calculate the percentage of doses taken at
correct time intervals.
Results: 43 patients (52%) were randomised to active counselling, and 40 (48%) were controls
(standard management). The intervention effect (difference in timing adherence pre- to post-
intervention between the 2 groups) was 13.4% (CI 5.1 to 21.7), p = 0.002. Parkinson motor scores
did not change significantly (active group 0.1, CI -3.4 to 3.7) versus controls (4.5, CI 1.6 to 7.1), p
= 0.06.
Conclusion: Timing adherence, but not motor scores, improves by providing patients with extra
information. Therapy timing is of potential importance in Parkinson's disease management.
Trial registration number: NCT00361205
Background
Patients with Parkinson's disease (PD) depend on medi-
cation for relief of motor symptoms, and for this reason
are often assumed to medicate very carefully. Overall,
medication adherence is very good, but a subset of 15 to
20% of cases take less than 80% of the total prescribed
dose[1,2], although the limit of 80% of tablet intake is
often applied, this is arbitrary and does not have a strong
pharmacological basis[3]. However, irregular timing  of
drug ingestion is almost universal[2], perhaps contributed
by fluctuating symptoms and drug regimen complexity.
Pulsatile dopaminergic stimulation in the basal ganglia is
implicated in the development and manifestation of
motor complications of advancing PD[4]. The mecha-
nism of motor complications is complex but may relate
partly to erratic absorption and short half-life of levodopa
causing fluctuating serum and brain drug levels and
abnormal pulsatile stimulation of striatal dopamine
receptors [5,6] contrasting with more continuous neurone
firing under normal circumstances [7,8]. In early disease
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the dopamine neurones have the capacity to buffer varia-
tions in striatal dopamine levels, but as the disease
progresses fluctuating plasma dopamine levels correlate
with alternating high and low striatal dopamine levels
causing pulsatile stimulation clinically manifesting as
emerging motor fluctuations [9].
Irregular medication intake is likely to contribute to peaks
and troughs in serum and brain drug levels. In other dis-
eases, patient adherence to prescribed medication
improves through simplifying drug regimens[10,11], pro-
viding additional education[12,13], counselling and
behavioural approaches [14-16] and providing reminder
packaging[17]. We tested the effect on the timing of med-
icine ingestion of an educational approach, in which
patients were given detailed additional information about
the continuous dopaminergic theory[4].
Methods
Patients attending a regional movement disorder clinic
with idiopathic PD (by UK Brain Bank criteria)[18] and
prescribed one or more antiparkinson drug (including
dopamine agonist or levodopa) were invited to partici-
pate. Patients who were unable to manipulate the elec-
tronic pill monitoring bottles, or whose adherence would
be adversely affected by using the electronic pill monitor-
ing bottles (e.g. those reliant on an adherence aid) were
excluded. If a carer normally assisted with patient's medi-
cation, they were asked to use the MEMS containers. The
study received ethics approval from the South Glasgow
Hospitals Ethics Committee and signed consent was
obtained. The informed consent procedure was the same
for active and control groups, and patients were not
advised that some would receive special educational
instructions.
Patients were randomly assigned (computer generated
and placed in opaque envelopes) to either the active
(counselled) or control groups. Randomisation preceded
baseline clinical assessment and issuing of MEMS bottles.
Baseline assessments of unified Parkinson's disease rating
scale (UPDRS)[19], Hoehn and Yahr[20], Schwab and
England[21], mini-mental state examination[22], geriat-
ric depression score[23] and quality of life score (PDQ
39)[24] were performed. All clinical recordings were blind
to patient group and performed in an 'on' state. The
UPDRS 3 and adverse events were recorded at each visit.
The quality of life score (PDQ 39) was repeated at the final
visit.
All antiparkinson drugs were monitored during two 3
month periods (before and after the educational interven-
tion) using electronic monitoring pill bottles (MEMS®,
Aardex, Switzerland), that record the time and date of bot-
tle opening. Individual tablet strengths were given a
MEMS container e.g. ropinirole 7 mg three times daily
required one MEMS container for each of 5 mg and 2 mg
tablets.
After the first 3-month period of MEMS monitoring,
patients in the active group were given verbal and written
information about the continuous dopaminergic theory
(one A4 page, Additional file 1), and tailored written
guidance on optimal medicine timing for their drug regi-
men. The counselling (by one investigator, KG) explained
that in health, brain dopamine is constant, and that fluc-
tuations from Parkinson's medications should be mini-
mised to simulate normal dopamine levels. At the time of
the intervention, individual baseline MEMS results had
not been processed, and all patients in the active group
were given the same information. Control patients
received standard care, but also had medication intake
monitored using the MEMS device. All patients were seen
every 3 months. During the study medication was
adjusted according to clinical need. The increase in levo-
dopa equivalent units during the study period was calcu-
lated according to established formula[25].
Timing adherence (the percentage of doses taken at the
correct time interval) was calculated using time intervals
during a 24-hour day which optimise the pharmacoki-
netic profile, plus a 25% allowance, eg. 3 times daily med-
ication is satisfactory at between 6 and 10 hours Selegiline
5 mg twice daily was excluded from analysis as the second
dose is taken at lunchtime to avoid sleep disturbance.
Adherence data were downloaded from the MEMS con-
tainers using Powerview® software (Aardex, Switzerland).
Analysis
Data are presented as mean and 95% confidence interval
(CI) when normally distributed, otherwise median and
interquartile (IQ) range. Groups were compared using
unmatched t-tests for parametric data and Mann-Whitney
for non-parametric data. The primary end point was a dif-
ference in timing adherence between groups. Analysis was
carried out by intent to treat (using last observation car-
ried forward, and patients completing the baseline moni-
toring). To detect a difference of 15% after intervention,
using an estimated SD of 20% for timing compliance,
gave a sample size of 58 patients (80% power, two-sided).
This 15% difference was arbitrary, since clinical signifi-
cance is not known in PD. To allow for drop-out, it was
planned for 80 patients to be recruited. Secondary end
points were differences in changes in UPDRS 3 and qual-
ity of life (PDQ 39) between groups. Statistical analysis
used Prism 3 (GraphPad®, CA, USA).
Results
Of 89 patients asked to participate, 6 (7%) declined (Fig-
ure 1). Of the remaining 83, 43 were randomised to theBMC Neurology 2007, 7:20 http://www.biomedcentral.com/1471-2377/7/20
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active group and 40 to the control group. Fourteen
patients dropped out during the first 3-month monitoring
period, 10 from the active group (2 withdrew consent
after baseline assessment, 1 died, and 7 had problems
with the electronic monitoring bottles).
Four control patients dropped out (3 had problems with
the bottles, 1 withdrew consent). There were no signifi-
cant differences in baseline characteristics in patients who
dropped out versus those continuing. Baseline adherence
data were therefore available for 69 patients (33 in the
active group and 36 in the controls, Table 1).
At baseline, timing adherence was a median of 17% (IQ
9–51) in the active group versus 21% (IQ 10–59) for con-
trols, a non-significant difference. Other parameters did
not differ significantly between active and control groups
(Table 1). Timing adherence was significantly better for
once daily drugs (median 82%, IQ 70–93) than drugs pre-
scribed twice daily (33%, IQ 4–47) or more frequently (p
< 0.0001)(Figure 2).
In the post-intervention period 17 patients dropped out,
10 from the active group, and 7 from the control group
(Figure 1). Post-intervention adherence data were evalua-
ble for 52 patients (23 active, 29 control)(Table 1). After
the intervention timing adherence was significantly better
in the active group at a median of 39% (IQ 22–58) com-
pared to a median of 20% (IQ 10–47) in the control
group (p = 0.007). The intervention effect (difference in
timing adherence pre- to post-intervention between the 2
groups) was 13.4% (CI 5.1 to 21.7), p = 0.002. After
excluding drugs taken once daily from analysis, the inter-
vention effect was 23.1% (CI 11.7 to 34.5), p = 0.0001.
There were no significant differences between UPDRS 3 or
quality of life scores or adverse events between groups
before intervention (Table 1). The PDQ single index score
increased by a mean of 6.0 (CI 2.3 to 9.7) for the active
group, versus a mean change of 3.5 (CI -1.6 to 8.6) in con-
trols (p = 0.4). The mean change in UPDRS 3 was 0.1 (CI
-3.4 to 3.7) in the active group versus 4.5 (CI 1.6 to 7.1)
in controls (p = 0.06).
There were no significant differences in frequency or type
of adverse events between groups (active group 1.5
adverse events per patient, versus 1.1 in controls). The
commonest adverse effects were in declining frequency:
insomnia, sleepiness, dyskinesia, and nausea.
Discussion
This is the first study to report an improvement in the tim-
ing of tablet intake in Parkinson's Disease (through any
mechanism), but there was no change in Parkinson motor
score, or quality of life scores. The response in timing
adherence was however variable, between a 23% worsen-
ing and a 96% improvement in actively counselled
patients, and control patients showed significantly worse
overall medication timing. This may be due in part to
waning novelty of the technique, between the first and
second 3-month monitoring period. Deterioration in con-
trol group adherence figures post-intervention is reported
elsewhere[26]. The majority of patients found regularisa-
tion of medicine-taking difficult; reasons include forget-
fulness and are well documented in PD[1].
Timing adherence is based on a 24 hour day, rather than
waking hours. This matches the concepts of the continu-
ous dopaminergic theory, namely that smoother symp-
tom control results from continuous, rather than
pulsatile, drug delivery. Although patients frequently
medicate preferentially in the daytime, which lowers their
timing adherence, we did not adjust our results to account
for this. The overnight problems of Parkinson symptoms,
and the continuous dopaminergic theory, both argue
against such an approach.
Drop-out from studies with electronic pill-bottle monitor-
ing is expected[27]. Although adverse events may contrib-
ute, this is commoner following therapy initiation[28],
while our patients were on established medication. Our
monitoring was prolonged and repeated, typically encom-
CONSORT diagram of study Figure 1
CONSORT diagram of study.BMC Neurology 2007, 7:20 http://www.biomedcentral.com/1471-2377/7/20
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passing several medications taken several times a day,
which contrasts with studies of monotherapy or twice-
daily medication[29]. Limitations in our study are as fol-
lows. Firstly, a substantial proportion of patients were
unable or unwilling to use MEMS containers (totalling 27
of 83 patients, 32.5%), which reduces adherence data for
intention to treat analysis of the primary outcome. How-
ever, clinical scoring was continued in all of these cases.
Secondly, the level at which sub-optimal adherence
becomes clinically important in PD is not known, and our
study does not assist in defining this. Thirdly, we underes-
timated the variability of timing adherence, which was
unreported at the time of planning this study. This should
be considered in designing further studies in this area.
Many interventions to improve therapy adherence have
been tested[30], but this is the first such study in Parkin-
son's disease. The vast majority of studies used pill counts,
self report or physician/nurse assessment to measure
adherence despite well-recognised shortcomings of these
methods [31]. Most interventions involve multiple com-
ponents[30], leaving uncertainty as to which aspects have
a positive effect. We therefore chose an intervention with
3 components (verbal and written information, and tai-
lored timing guidance) but had a single focus of improv-
ing timing adherence. The resulting timing adherence
improvement was similar to that from individualised cue-
dose training (linking medicine taking to daily activities)
in diabetes[14]. Another interventional approach is to
inform the patient of their own prior dosing history from
the electronically monitored data[32].
In our study drugs taken once daily were taken more reg-
ularly than more complicated regimens, which is consist-
ent with a systematic review of 76 electronic monitoring
studies[33]. Pharmaceutical development of more once
daily antiparkinson preparations may help ease the proc-
ess of medicine taking.
There was no significant difference in UPDRS 3 before and
after the intervention. Quality of life deteriorated, but is
more influenced by non-motor factors such as depression.
We did not find an association between deterioration in
domains of the PDQ score and UPDRS changes, in partic-
ular considering items which might respond to increasing,
or regularising, dopaminergic therapy (bodily discomfort,
mobility). Clinical improvement is reported in some
adherence studies (e.g. epilepsy[34]), but is by no means
universal[14].
Conclusion
Timing adherence improves by providing patients with
extra information. Therapy timing is of potential impor-
tance in Parkinson's disease management. Further larger,
longer-term studies are necessary to determine whether
improved medication timing is sustainable, and whether
there are beneficial effects associated with the regularity of
medication intake in Parkinson's disease.
Table 1: Patient baseline characteristics by group
Pre-Intervention Post-Intervention
Active (n = 33) Control (n = 36) Active (n = 23) Control (n = 29)
Males (%) 62% 51%
Age (years) 61 (10) 66 (13)
Prescribed levodopa (%) 21 (62%) 25 (71%) 18 (78%) 22 (76%)
Levodopa dose (mg) 485 (252) 538 (389) 511 (306) 670 (380)
Prescribed dopamine agonist (%) 25 (74%) 25 (71%) 18 (78%) 18 (62%)
Change in levodopa equivalent units - - 51 (148) 70 (149)
Number of PD drugs 2.4 (1.1) 2.4 (1.3) 2.4 (1.2) 2.2 (1.5)
Number of PD daily doses 4.0 (2.5) 4.0 (1.3) 4 (0.8) 4 (1.2)
Number of PD tablets per day 9 (5) 9.1 (5) 9.5 (5) 9 (5)
Number of non-PD drugs per day 2.6 (3) 2.9 (1.8) 2.5 (3) 3.5 (4)
Total number of tablets per day 12 (5) 12 (5) 13 (7) 12 (7)
Number of patients with carer 6 (18%) 7 (19%)
Duration of PD (years) 7.5 (6) 6.3 (4.1) - -
UPDRS 3 30 (12) 24 (13) 29 (14) 28 (14)
Hoehn & Yahr 2.4 (0.7) 2.4 (0.7) 2.5 (0.7) 2.5 (0.7)
Schwab & England 78 (10) 76 (14) 71 (18) 73 (15)
MMSE 28 (2) 28 (2) - -
Geriatric depression score 12 (6) 10 (7) - -
PDQ SI 30 (15) 26.5 (18) 36 (15) 28 (14)
Timing adherence, median (IQ) 17% (9–51) 21% (10–59) 39% (22–58) 20% (10–47)*
Data are mean (standard deviation) unless otherwise stated. PD = Parkinson's disease, UPDRS = Unified Parkinson's disease rating scale, MMSE = 
mini mental state examination, PDQ 39 SI = Parkinson's disease quality of life single index, IQ = interquartile range. *p = 0.007. There were no 
other significant differences between groups.BMC Neurology 2007, 7:20 http://www.biomedcentral.com/1471-2377/7/20
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Abbreviations
CI = confidence interval, IQ = interquartile range, MEMS
= medication event monitoring system (the electronic
monitoring bottles), MMSE = mini-mental state examina-
tion, PD = Parkinson's disease, PDQ 39 = Parkinson's dis-
ease quality of life questionnaire, UPDRS = unified
Parkinson's disease rating score.
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